About this trial
This study will compare total shoulder arthroplasty (TSA) with an augmented glenoid component and reverse shoulder arthroplasty (RSA) procedures, in participants with advanced glenohumeral osteoarthritis aged 65 years and older, who also present with greater than 15 degrees of glenoid retroversion, in the context of a prospective, randomized controlled trial to determine the optimal treatment in this patient population.
Eligibility criteria
Qualifiers
Diagnosis of idiopathic shoulder OA.
Patients who have failed standard non-surgical management of their shoulder OA who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for at least 6 months. Medical management will be defined as: a) The use of drugs including analgesics and nonsteroidal anti-inflammatory drugs, b) Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.), c) Activity modification
Imaging, and intra-operative findings confirming advanced glenohumeral cartilage loss
Patients with a glenoid deficiency and >15 degrees of glenoid retroversion up to a maximum of 26 degrees of glenoid retroversion (i.e. -15.1, -17, -20…etc.)
Disqualifiers
Active joint or systemic infection
Rotator cuff arthropathy
Significant muscle paralysis
Charcot's arthropathy
Trial design
Treatments tested in this trial
- Total Shoulder Arthroplasty + augmented glenoid component
- Reverse Shoulder Arthroplasty